Financial Information - EyePoint Pharmaceuticals, Inc. provided an updated investor presentation on January 13, 2025, including financial information as of December 31, 2024[6] Clinical Plans and Achievements - The company highlighted its 2025 clinical plans and recent corporate and clinical achievements in a press release issued on the same date[7] Transparency and Communication - The investor presentation and press release are available on the company's website, indicating a focus on transparency and investor communication[6][7]

– Enrollment exceeding expectations in DURAVYU™ Phase 3 wet AMD clinical trials with LUGANO over 50% enrolled and LUCIA recruiting ahead of schedule – – Positive Phase 2 VERONA clinical trial of DURAVYU for DME met primary and secondary endpoints – – $371 million of cash and investments on December 31, 2024, providing cash runway into 2027 beyond topline DURAVYU Phase 3 wet AMD data expected in 2026 – WATERTOWN, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a compa ...

Core Insights - EyePoint Pharmaceuticals, Inc. is focused on developing innovative therapeutics for serious retinal diseases, with a commitment to improving patient lives [2][3] Company Overview - EyePoint is a clinical-stage biopharmaceutical company utilizing its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery [2] - The lead product candidate, DURAVYU, is an investigational treatment for VEGF-mediated retinal diseases, currently in Phase 3 trials for wet age-related macular degeneration (wet AMD) and has completed Phase 2 trials for diabetic macular edema (DME) [2][4] - The company anticipates discussions with regulatory agencies in Q2 2025 regarding pivotal program plans based on positive Phase 2 results from the VERONA trial in DME [2] Pipeline Programs - Additional pipeline programs include EYP-2301, a TIE-2 agonist, and razuprotafib, both formulated in Durasert E to potentially enhance outcomes in serious retinal diseases [3] - Durasert technology has been safely administered to thousands of patient eyes across four FDA-approved products for various disease indications [3] Upcoming Investor Conferences - EyePoint management will participate in the Leerink Partners Global Healthcare Conference on March 11, 2025, and the Barclays 27th Annual Global Healthcare Conference on March 12, 2025 [5]

WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 5, 2025 to report its fourth quarter and full-year 2024 financial results and highlight recent corporate developments. To access the live conference call, please register ...

– Company presentation scheduled on Tuesday, March 4th at 9:10am ET – – EyePoint to provide enrollment update for ongoing DURAVYU™ Phase 3 pivotal program in wet AMD and additional subgroup analyses from Phase 2 VERONA clinical trial in DME – WATERTOWN, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. ...

EyePoint Pharmaceuticals (EYPT) Update / Briefing February 05, 2025 08:00 AM ET Company Participants Jay Duker - President & CEORamiro Ribeiro - Chief Medical OfficerYigal Nochomovitz - DirectorKambiz Yazdi - Vice President - Equity ResearchGraig Suvannavejh - Managing Director Conference Call Participants Tessa Romero - Equity AnalystTyler Van Buren - Managing Director, Senior Biotech Equity Research AnalystYatin Suneja - Biotechnology Research AnalystJennifer Kim - AnalystColleen Kusy - Senior Research An ...

- Primary endpoint achieved by both DURAVYU doses (1.34mg and 2.7mg) with extended time to first supplemental injection versus aflibercept control – - DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a 24-week gain of +7.1 letters and anatomical improvement of 76 microns reduction in CST paired with reduction in treatment burden of two-thirds – Favorable safety profile continues with no DURAVYU-related ocular or systemic SAEs – – Phase 3 non-inferiority pivotal program initiation a ...

- Primary endpoint achieved by both DURAVYU doses (1.34mg and 2.7mg) with extended time to first supplemental injection versus aflibercept control – - DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a 24-week gain of +7.1 letters and anatomical improvement of 76 microns reduction in CST paired with reduction in treatment burden of two-thirds – Favorable safety profile continues with no DURAVYU-related ocular or systemic SAEs – – Phase 3 non-inferiority pivotal program initiation a ...

Group 1 - The marketplace channel Haggerston BioHealth offers exclusive stock tips focused on Pharma, Biotech, and Healthcare, providing access to investment bank-grade financial models and research [1][2] - The group caters to both novice and experienced biotech investors, offering insights on catalysts, buy and sell ratings, product sales forecasts, and integrated financial statements [2] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group and has compiled detailed reports on over 1,000 companies [2]

Core Insights - EyePoint Pharmaceuticals, Inc. is focused on developing innovative therapeutics for serious retinal diseases and will have its CEO participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025 [1][2] Company Overview - EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company that utilizes proprietary bioerodible Durasert E technology for sustained intraocular drug delivery [3] - The lead product candidate, DURAVYU (formerly EYP-1901), is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and Phase 2 trials for diabetic macular edema (DME) [3][4] - Full topline data from the Phase 2 trial in DME is expected in Q1 2025, with topline data from Phase 3 trials in wet AMD anticipated in 2026 [3] Product Pipeline - Pipeline includes EYP-2301, a TIE-2 agonist, and razuprotafib, both formulated in Durasert E to potentially enhance outcomes in serious retinal diseases [4] - The Durasert drug delivery technology has been safely used in thousands of patient eyes across four FDA-approved products [4] Licensing and Regulatory Status - Vorolanib, a key component of DURAVYU, is exclusively licensed to EyePoint for localized treatment of ophthalmic diseases outside of certain Asian markets [5] - DURAVYU has been conditionally accepted by the FDA as the proprietary name for EYP-1901, but it remains an investigational product and has not yet received FDA approval [5]